- [Resource Hub](/)
- [Resource](/?resource-type=poster#library)
- Development and analytic validation of an ARv7 / PSMA dual biomarker circulating tumor cell assay

# Development and analytic validation of an ARv7 / PSMA dual biomarker circulating tumor cell assay

Prostate cancer drug targets and biomarkers that plasma cfDNA cannot report are carried on circulating tumor cells; this AACR 2024 poster describes the development and analytic validation of a dual biomarker assay that measures ARv7 and PSMA expression on the same individual CTC.

Presented by RareCyte.

Read or download to see:

- Sensitivity and specificity were measured on spiked model cell lines, not on patient CTCs. Known positive and negative cell lines spiked into normal donor blood gave 83% sensitivity and 98% specificity for ARv7 (22Rv1 against BT474), and 97% and 99% for PSMA (LNCaP against PC3), aggregated over more than 1000 model CTCs from 15 tested slides in each population run on 3 separate days. These are per-cell biomarker-call rates on cells the workflow had already recovered, not CTC detection rates.

- Both biomarkers are read on the same individual CTC, and the phenotypes came apart. With per-cell positivity thresholds of MFI 140 for ARv7 and MFI 200 for PSMA applied across nine Stage IV prostate cancer samples, patient #2 ran 96.5% ARv7-positive and 0% PSMA-positive over 384 CTCs, while patient #8 ran 27.9% ARv7-positive and 98.8% PSMA-positive over 86 CTCs — the only two samples with more than nine CTCs recovered.

- The nine-sample patient series was run to demonstrate feasibility, and the performance claim stays with the cell lines. CTC counts ranged from 1 to 384 per sample; blood was collected into AccuCyte tubes, density-separated and spread to slides, stained on a Leica BOND RX, scanned on CyteFinder, confirmed by a trained reviewer, then scored in CyteMapper. The poster reports no patient outcomes and no treatment comparison.

[Download poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf)

Your browser doesn’t support embedded PDFs.
[Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf) to view it.

[Back to all resources](/#library)
## Related resources
[Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) CyteFinder 2025
### Development of a CTC Based Assay to Characterize MAOA Expression in Metastatic Prostate Cancer
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) [Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) CyteFinder 2024
### New Discoveries in HER2 Detection: A Novel Method of Multimodal Detection of HER2 from a Single Tube of Blood
[Watch Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) CyteFinder 2024
### Development and validation of an assay for the characterization of SSTR2 expression on CTCs from liquid biopsies
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11863877/) CyteFinder The Journal of Liquid Biopsy 2023
### Liquid biopsy kinetics and detection of ERBB2 amplification/HER2-positivity in refractory hepatocellular carcinoma
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11863877/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/b4fe65d132e5579cb5e0a30c9bee5d7ff7f632ab.pdf) CyteFinder 2023
### Novel method for the detection and evaluation of disease biomarkers on white blood cells from liquid biopsies
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/b4fe65d132e5579cb5e0a30c9bee5d7ff7f632ab.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/51dd5a4aee911d671443d768abcfc0b4f83899e8.pdf) CyteFinder 2020
### Validation of a dual-marker ARv7/SYP assay for CTC characterization
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/51dd5a4aee911d671443d768abcfc0b4f83899e8.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/558dd9bd9ab2fa4c95bbc225309f5026bd3b7094.pdf) CyteFinder 2020
### Analytic validation of an assay to detect androgen receptor splice variant ARv7 protein expression on circulating tumor cells from prostate cancer patients
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/558dd9bd9ab2fa4c95bbc225309f5026bd3b7094.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/600f37993438d761629a40034f7702ebe3e46ee3.pdf) CyteFinder 2020
### Investigation of custom biomarkers on circulating tumor cells from clinical samples using RarePlex Developer Kits
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/600f37993438d761629a40034f7702ebe3e46ee3.pdf) [Video](https://www.youtube.com/watch?v=A0dhlNEaohs) CyteFinder 2020
### RarePlex Assays: Design and Analytical Validation
[Watch Video](https://www.youtube.com/watch?v=A0dhlNEaohs) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/d6eac85be7627ae4445c6583acad89fea879177d.pdf) CyteFinder 2020
### Validation of an assay to detect programmed death-ligand 1 (PD-L1) expression on circulating tumor cells
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/d6eac85be7627ae4445c6583acad89fea879177d.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/5962be5f1b2b288f2c069f7bd7b54890839f426a.pdf) CyteFinder 2019
### Custom biomarker investigation of circulating tumor cells using RarePlex® Developer Kits
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/5962be5f1b2b288f2c069f7bd7b54890839f426a.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/886b7272733f331d2bd933c9cfa2bb97ce0e9542.pdf) CyteFinder 2018
### Novel multi-parameter assays for investigational phenotyping of circulating tumor cells
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/886b7272733f331d2bd933c9cfa2bb97ce0e9542.pdf)